P-147Final analysis: phase II trial of...

Annals of Oncology 2016 / 06 Vol. 27; Iss. suppl 2

P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

Yuki, S., Komatsu, Y., Nakatsumi, H., Kawamoto, Y., Muranaka, T., Sawada, K., Tsuji, Y., Hosokawa, A., Nakamura, M., Muto, O., Sasaki, T., Iwanaga, I., Hatanaka, K., Sato, A., Eto, K., Furukawa, K., T
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw199.141
Date:
June, 2016
File:
PDF, 66 KB
2016
Conversion to is in progress
Conversion to is failed